ALT

Business Context and Reporting Period

Company: PharmAthene, Inc. (Note: Metadata referenced Altimmune, Inc., but the filing text identifies the registrant as PharmAthene, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: PharmAthene is a biopharmaceutical company focused on developing biodefense countermeasures against biological and chemical weapons. Its primary revenue sources are cost-plus-fee contracts and grants from U.S. government agencies, including the Department of Defense (DoD), BARDA, and NIAID. Key product candidates include SparVax (anthrax vaccine), Valortim (anthrax monoclonal antibody), and Protexia (nerve agent countermeasure).

Key Financial Metrics

Note: The company reported a negative working capital position and a stockholders' equity deficit as of September 30, 2010.

Material Changes vs. Prior Period

• Revenue Decline: Revenue for the nine months ended September 30, 2010, decreased to $14.14 million from $20.42 million in the prior year period. This decline was primarily driven by reduced activity in the Protexia program (DoD contract) and the Valortim program (due to a partial clinical hold), partially offset by increased activity in the SparVax program.
• Expense Reduction: Operating expenses decreased significantly. Research and Development (R&D) expenses fell to $17.06 million (nine months 2010) from $23.93 million (nine months 2009), largely due to the wind-down of the RypVax plague vaccine program and reduced activity in Valortim and Protexia. General and Administrative (G&A) expenses dropped to $12.63 million from $15.79 million, aided by lower stock-based compensation and personnel costs.
• Net Loss Improvement: The net loss for the nine months ended September 30, 2010, was $18.67 million, an improvement from the $26.61 million loss in the same period in 2009. This improvement was driven by lower operating expenses and a gain of $0.38 million on the change in market value of derivative instruments, compared to a loss of $0.30 million in the prior year.
• Debt Reclassification: Convertible notes maturing in July 2011 were reclassified from long-term to current liabilities, increasing current liabilities to $30.03 million.

Guidance, Outlook, Risks, and Unusual Items

Management Commentary and Outlook

• Protexia Program: The DoD has deferred a decision on funding advanced development of Protexia, potentially for several years, due to budget constraints and concerns regarding the duration of protection. The company expects to incur wind-down costs in late 2010 and early 2011 and is evaluating potential asset write-downs.
• Valortim Program: The FDA placed a partial clinical hold on Valortim following adverse reactions in a Phase I trial. The company is conducting an investigation and plans to propose a new IV dose-escalation study with a slower infusion rate. BARDA has indicated it will not act on funding requests until the hold is lifted.
• SparVax Program: Revenue increased due to higher program activity. The company received positive feedback from BARDA regarding performance improvements following a previous evaluation.
• Liquidity: The company relies on government contracts and equity financing. A bid protest in March 2010 caused a "stop-work" order and delayed cash collections, necessitating additional financing.

Subsequent Events (Post-September 30, 2010)

• November 2010 Offering: The company closed a registered public offering of 4.3 million shares at $3.50 per share, generating estimated net proceeds of approximately $14.1 million.
• Debt Conversion: Simultaneously with the offering, certain affiliates and directors converted approximately $9.8 million of convertible notes into roughly 3.9 million shares of common stock. Approximately $12.0 million in principal and interest remained on the remaining notes as of November 11, 2010.

Risks and Contingencies

• Delisting Risk: The company received notice from NYSE Amex regarding non-compliance with stockholders' equity requirements. A compliance plan was accepted, but failure to meet standards by January 26, 2012, could result in delisting.
• SIGA Litigation: The company is involved in ongoing litigation against SIGA Technologies regarding licensing rights for the drug candidate ST-246. Trial is scheduled to commence on January 3, 2011. No accrual has been made as an unfavorable outcome is not deemed probable.
• Government Funding Dependence: Substantially all revenue is derived from U.S. government contracts, which are subject to budget cuts, termination for convenience, and audit adjustments.
• Derivative Liabilities: The company has significant derivative liabilities ($2.53 million) related to stock purchase warrants, which are re-measured at fair value each period, impacting net income.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $14.1 million raised in November 2010 to cover the remaining $12.0 million in convertible debt due in July 2011 and ongoing operating losses.
• Protexia Asset Valuation: Monitor the fourth-quarter 2010 analysis regarding potential write-downs of Protexia-related assets following the DoD's deferral of funding.
• Valortim Clinical Hold: Confirm the FDA's decision on the proposed dose-escalation study and the timeline for lifting the partial clinical hold, as this is a prerequisite for BARDA funding.
• NYSE Amex Compliance: Track progress against the compliance plan to ensure the company meets stockholders' equity requirements by January 2012 to avoid delisting.
• SIGA Litigation Outcome: Assess the potential financial impact of the SIGA lawsuit, including the risk of dismissal or counterclaim damages, given the trial date in early 2011.